Janus Henderson Group PLC Purchases New Shares in Bausch + Lomb Co. (NYSE:BLCO)

Janus Henderson Group PLC acquired a new stake in Bausch + Lomb Co. (NYSE:BLCO - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 49,633 shares of the company's stock, valued at approximately $957,000.

A number of other large investors also recently bought and sold shares of BLCO. HighTower Advisors LLC lifted its stake in Bausch + Lomb by 14.7% during the third quarter. HighTower Advisors LLC now owns 24,661 shares of the company's stock worth $476,000 after purchasing an additional 3,164 shares in the last quarter. Cinctive Capital Management LP acquired a new position in Bausch + Lomb during the 3rd quarter worth about $870,000. Verition Fund Management LLC acquired a new position in Bausch + Lomb during the 3rd quarter worth about $302,000. Charles Schwab Investment Management Inc. boosted its holdings in Bausch + Lomb by 80.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 29,755 shares of the company's stock valued at $576,000 after acquiring an additional 13,302 shares during the period. Finally, River Road Asset Management LLC grew its position in Bausch + Lomb by 4.4% in the 3rd quarter. River Road Asset Management LLC now owns 2,020,414 shares of the company's stock valued at $38,974,000 after acquiring an additional 85,987 shares in the last quarter. Institutional investors and hedge funds own 11.07% of the company's stock.

Analyst Ratings Changes

BLCO has been the subject of several recent research reports. Morgan Stanley lowered shares of Bausch + Lomb from an "overweight" rating to an "equal weight" rating and set a $19.00 price objective for the company. in a research note on Monday, December 2nd. Citigroup cut shares of Bausch + Lomb from a "buy" rating to a "neutral" rating and decreased their price target for the company from $24.00 to $22.00 in a research report on Wednesday. Bank of America restated an "underperform" rating and issued a $18.00 price target on shares of Bausch + Lomb in a research note on Thursday. Evercore ISI upgraded Bausch + Lomb from an "in-line" rating to an "outperform" rating and increased their price objective for the company from $19.00 to $25.00 in a research note on Tuesday, October 15th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Bausch + Lomb in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $20.58.

Bausch + Lomb Stock Down 0.1 %

Shares of NYSE BLCO traded down $0.02 during midday trading on Friday, hitting $18.60. 756,145 shares of the company's stock were exchanged, compared to its average volume of 562,004. The firm's fifty day simple moving average is $19.87 and its 200-day simple moving average is $17.52. The company has a market cap of $6.55 billion, a PE ratio of -17.71, a P/E/G ratio of 1.74 and a beta of 0.43. Bausch + Lomb Co. has a twelve month low of $13.16 and a twelve month high of $21.69. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.57 and a quick ratio of 0.95.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of $0.16 by $0.01. The company had revenue of $1.20 billion for the quarter, compared to analysts' expectations of $1.17 billion. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The firm's revenue for the quarter was up 18.8% on a year-over-year basis. During the same quarter last year, the company earned $0.22 earnings per share. Research analysts predict that Bausch + Lomb Co. will post 0.6 EPS for the current fiscal year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.